title: Vaccinate before the next pandemic?
authors.affiliation: Novartis Vaccines and Diagnostics, Cambridge, Massachusetts 02139, USA. klaus.stohr@novartis.com
authors.forename: Klaus
authors.initials: K
authors.lastname: Stöhr
mesh_terms: D003362:Cost-Benefit Analysis; D004196:Disease Outbreaks / Q000517:prevention & control* / Q000706:statistics & numerical data; D014943:Global Health; D006801:Humans; D007252:Influenza Vaccines / Q000008:administration & dosage* / Q000009:adverse effects / Q000191:economics / Q000600:supply & distribution*; D007251:Influenza, Human / Q000191:economics / Q000453:epidemiology / Q000517:prevention & control* / Q000635:transmission; D013997:Time Factors; D014611:Vaccination / Q000009:adverse effects / Q000191:economics / Q000379:methods*
chemical_list: D007252:Influenza Vaccines
references.citation: N Engl J Med. 2008 Oct 9;359(15):1631-3
references.pmid: 18843132
references.citation: PLoS Med. 2010 May 04;7(5):e1000247
references.pmid: 20454566